Metraipolis › archive › dc_aa0488ffc8fe

Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model… — Europe PMC PMID:41104331

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41104331
DOI: 10.3389/fphar.2025.1498735
License (as archived): solo-consultazione
Archived: 2026-11-09T16:32:04.612Z
SHA-256 of the archived text: b70ae5af4573ce040b5705bfe2e4b8975c74167342d33b120f004e60cd433015
Stable URL of this page: https://metraipolis.com/documento/dc_aa0488ffc8fe

How to cite

Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model… — Europe PMC PMID:41104331 — Europe PMC (en), https://europepmc.org/article/MED/41104331 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_aa0488ffc8fe (Metraipolis archive dc_aa0488ffc8fe, sha256 b70ae5af4573ce040b5705bfe2e4b8975c74167342d33b120f004e60cd433015)

BibTeX

@misc{dcaa0488ffc8fe,
  title = {Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model… — Europe PMC PMID:41104331},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41104331},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_aa0488ffc8fe; sha256 b70ae5af4573ce040b5705bfe2e4b8975c74167342d33b120f004e60cd433015},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41104331. Agents can read the archived copy with the MCP tool read_document.